Science 37 Appoints Kelly Johnston McKee As Vice President , Strengthens Leadership With New Strategy Head

Science 37 announced the appointment of Kelly Johnston McKee as Vice President, Strategy & Transformation, a role focused on shaping the company’s future patient experience and supporting long-term growth through innovation and operational modernization. McKee will lead efforts to advance decentralized and hybrid trial models, strengthen collaboration across teams, and drive scalable approaches to clinical development.

With more than two decades of experience in clinical innovation and patient engagement, McKee is known for building high-performing ecosystems that improve trial enrollment, lower costs, and enhance the overall participant journey. Her background includes senior leadership positions at AstraZeneca/Evinova, Medidata, Vertex, Eli Lilly, Merck, and Sanofi, where she helped translate new ideas into enterprise-level solutions across clinical operations.

"Kelly’s expertise sits at the intersection of strategy, innovation, and execution, the exact space where Science 37 is focused," said Tyler Van Horn, CEO of Science 37. "Her ability to translate bold ideas into scalable impact will be instrumental as we advance next-generation patient experiences and deepen our industry partnerships."

In her new role, McKee will prioritize modernizing trial execution by streamlining workflows and accelerating organizational growth. She will also focus on developing next-generation, patient-centered trial experiences and fostering stronger patient communities.

"Science 37 has long challenged conventional thinking around access and execution in clinical trials,” said McKee. “As the industry moves beyond experimentation, the opportunity now is to scale innovation and optimize experiences in a way that is operationally sound and holds meaningful value for patients, sites, and sponsors. I am excited to help shape that next phase.”  

Additionally, McKee will work to expand Science 37’s strategic partnerships and advisory networks while strengthening the company’s brand as a leader in decentralized and hybrid clinical trials, reinforcing its position in a rapidly evolving research landscape.